Cardiovascular Disease and Risk Factors in PCOS Women of Postmenopausal Age: A 21-Year Controlled Follow-Up Study
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is associated with the metabolic syndrome and, consequently, with a potentially increased risk of cardiovascular disease (CVD) and related mortality later in life. Studies regarding CVD and mortality in PCOS women well into the postmenopausal age are lacking. OBJECTIVE: Our objective was to examine whether postmenopausal PCOS women differ from controls regarding cardiovascular risk factors, myocardial infarction (MI), stroke and mortality. DESIGN AND SETTING: We conducted, at a university hospital, a prospective study of 35 PCOS women (61-79 yr) and 120 age-matched controls. The study was performed 21 yr after the initial study. PARTICIPANTS: Twenty-five PCOS women (Rotterdam criteria) and 68 controls participated in all examinations. Data on morbidity were based on 32 of 34 PCOS women and on 95 of 119 controls. INTERVENTIONS: INTERVENTIONS included reexamination, interviews, and data from the National Board of Health and Welfare and from the Hospital Discharge Registry. MAIN OUTCOME MEASURES: Blood pressure, glucose, insulin, triglycerides, total cholesterol, high- and low-density lipoprotein, apolipoprotein A1 and B, fibrinogen, and plasminogen activator inhibitor antigen were studied. Incidences of MI, stroke, hypertension, diabetes, cancer, cause of death, and age at death were recorded. RESULTS: PCOS women had a higher prevalence of hypertension (P = 0.008) and higher triglyceride levels (P = 0.012) than controls. MI, stroke, diabetes, cancer, and mortality prevalence was similar in the two cohorts with similar body mass index. CONCLUSIONS: The well-described cardiovascular/metabolic risk profile in pre- and perimenopausal PCOS women does not entail an evident increase in cardiovascular events during the postmenopausal period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PCOS is linked with increased prevalence of cardiometabolic risk factors, including dyslipidemia [10,11,12,13], hypertension [13,14,15], chronic inflammation, and impaired glucose tolerance [16,17], as well as overweight and obesity [18,19].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [13]
In the citing paper
“Women with PCOS experience increased cardiometabolic risk—including the metabolic syndrome, hypertension, insulin resistance, obesity and dyslipidemia—predisposing them to increased risk for diabetes and cardiovascular disease (CVD).2,10,17, 18, 19, 20”
From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [20]
In the citing paper
“The results regarding prevalence of T2DM in women with PCOS over the age of 40 years are conflicting.”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“The lack of significance might be due to the similar BMI between groups in that study and the fact that controls caught up in WHR during the 21-year follow-up period (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
In the citing paper
“In our previous study of another cohort of women with PCOS and controls, where the women had a mean age of 72 years and similar BMI, the prevalence of T2DM was 22% for women with PCOS compared with 14% for controls (not statistically significant) (Schmidt et al., 2011).”
From Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution (2020) · cites this paper as Schmidt et al., 2011
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760 · cited 1×
“risk of diabetes mellitus, cardiovascular disease (CVD) (13) and all-cause mortality (14).”
BackgroundGerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
Clauss, A. (1957) · Acta Haematologica · doi:10.1159/000205234 · Cited by 3,208
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“Diabetes, a strong risk factor for CVD, as well as insulin resistance and hyperinsulinemia are common among PCOS women of premenopausal (2, 4) and perimenopausal/early postmenopausal age (9, 17).”
BackgroundWalldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Cited by
Items 101–200 of 267
Forslund, M., Schmidt, J., Brännström, M., Landin‐Wilhelmsen, K., & Dahlgren, E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa840 · Cited by 31
Self-citationBaldani, D. P., Škrgatić, L., Cerne, J. Z., Ferk, P., Šimunić, V., & Geršak, K. (2013) · Biomedical Reports · doi:10.3892/br.2013.215 · Cited by 31
“…and compensatory hyperinsulinemia (3), disturbed secretion of adipokines (4) and an elevated risk for diabetes mellitus type 2 (T2DM) (5) and cardiovascular diseases (CVD) (6), the peroxisome proliferator-activated receptor gamma ( PPARG ) represents a strong candidate gene predisposing to PCOS.”
InfluentialZhang, S., He, H., Wang, Y., Wang, X., & Liu, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-34746-z · Cited by 30
Between mind and heart: Sex-based cognitive bias in cardiovascular disease treatment
Kentner, A. C., & Grace, S. L. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.02.002 · Cited by 30
Dwivedi, A. K., Vishwakarma, D., Dubey, P., & Reddy, S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad067 · Cited by 29
Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update
Profili, N. I., Castelli, R., Gidaro, A., Manetti, R., Maioli, M., Petrillo, M., Capobianco, G., & Delitala, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030698 · Cited by 29
“However, costs, timing, and local availability do not allow for its use in the general population.”
BackgroundEvaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome
Xavier, L. B., Sóter, M. O., Sales, M. F., de Oliveira, D. K. D., Reis, H. J., Cândido, A. L., dos Reis, F. M., Silva, I. D. F. O., Gomes, K. B., & Ferreira, C. N. (2017) · Gene · doi:10.1016/j.gene.2017.11.006 · Cited by 28
Androgen-Induced Cardiovascular Risk in Polycystic Ovary Syndrome: The Role of T Lymphocytes
Moulana, M. (2023) · Life · doi:10.3390/life13041010 · Cited by 27
Cheema, B. S., Vizza, L., & Swaraj, S. (2014) · Sports Medicine · doi:10.1007/s40279-014-0206-6 · Cited by 27
Kiconco, S., Tay, C. T., Rassie, K. L., Azziz, R., Teede, H. J., & Joham, A. E. (2022) · Clinical Endocrinology · doi:10.1111/cen.14647 · Cited by 25
“Two of the three studies that compared changes in systolic blood pressure (SBP) between groups suggested no significant difference,(48,50) while one study showed a significantly higher increase in mean SBP among women without PCOS than those with PCOS.(52) For comparisons within the PCOS group, two studies demonstrate…”
BackgroundResultAbalı, R., Celik, C., Taşdemir, N., Güzel, S., Alpsoy, Ş., Yüksel, A., & Celik, E. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.01.023 · Cited by 25
“showed no increased myocardial infarction, stroke or mortality despite a higher prevalence of hypertension and dyslipidemia [15].”
BackgroundGencer, M., Gazı, E., Hacıvelioğlu, S., Binnetoğlu, E., Barutçu, A., Türkön, H., Temız, A., Altun, B., Vural, A., Cevızcı, S., et al. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.07.032 · Cited by 25
“Many studies have evaluated various parameters associated with the development of cardiovascular events and found that cardiovascular events were not increased in PCOS patients [23,35].”
Polycystic ovaries – beyond menopause
Shah, D., & Bansal, S. (2013) · Climacteric · doi:10.3109/13697137.2013.828687 · Cited by 25
An overview of polycystic ovary syndrome in aging women
Çelik, Ö., & Köse, M. F. (2021) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2021.2021.0077 · Cited by 24
“with no heightened incidence of stroke, CVD or mortality (31).”
BackgroundInfluentialZoet, G. A., Meun, C., Benschop, L. H., Boersma, E. H., Budde, R. P. J., Fauser, B. C. J. M., de Groot, C. J. M., van der Lugt, A., Maas, A. H. E. M., Moons, K. G. M., et al. (2017) · BMC Women s Health · doi:10.1186/s12905-017-0415-x · Cited by 23
Polycystic Ovary Syndrome: Insights from Preclinical Research
Reckelhoff, J. F., Shawky, N. M., Romero, D. G., & Cardozo, L. L. Y. (2022) · Kidney360 · doi:10.34067/kid.0002052022 · Cited by 23
Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome
Pace, L. A., Markovic, D., Buyalos, R. P., Bril, F., & Azziz, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae527 · Cited by 22
Ramoglu, S., Yoldemir, T., Atasayan, K., & Yavuz, D. G. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13455 · Cited by 22
“Moreover, apart from these two factors, no other increase in any risk factor was determined in cardiovascular events.(26) Our study subgroups were compared according to the Rotterdam diagnostic criteria, blood pressure, age, HOMA-IR levels and BMI.”
ResultLuotola, K., Piltonen, T. T., Puurunen, J., Morin-Papunen, L. C., & Tapanainen, J. S. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1342793 · Cited by 21
Cussen, L., McDonnell, T., Miller, C., McIlroy, M., & O’Reilly, M. (2025) · Reproduction · doi:10.1530/rep-25-0102 · Cited by 22
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Underdal, M. O., Stridsklev, S., Oppen, I. H., Høgetveit, K., Andersen, M., & Vanky, E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00485 · Cited by 21
Longitudinal changes over three years in sex steroid hormone levels in women aged 70 years and over
Islam, R. M., Bell, R. J., Handelsman, D. J., Robinson, P. J., Wolfe, R. S., Davis, S. R., & the ASPREE Investigator Group (2020) · Clinical Endocrinology · doi:10.1111/cen.14401 · Cited by 21
Rooney, S., & Pendry, B. A. (2014) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2014.05.001 · Cited by 21
Polycystic ovary syndrome: clinical implication in perimenopause
Lenart-Lipińska, M., Matyjaszek‐Matuszek, B., Woźniakowska, E., Solski, J., Tarach, J. S., & Paszkowski, T. (2014) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2014.47988 · Cited by 21
“Furthermore, total mortality during 21-year follow-up period was similar in comparison to the control group despite the higher prevalence of cardiovascular risk factors among patients with PCOS [30].”
ResultCardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Armeni, E., & Lambrinoudaki, I. V. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180828154006 · Cited by 20
Changes in Metabolic Profile in the Women with a History of PCOS—A Long-Term Follow-Up Study
Jacewicz‐Święcka, M., & Kowalska, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103367 · Cited by 21
“Significant increase as well as no changes in WC and BMI have been described [47,50,61,62].”
BackgroundDoes the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age?
Azziz, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.09.034 · Cited by 20
Mahboobifard, F., Rahmati, M., Niknam, A., Rojhani, E., Momenan, A. A., Azizi, F., & Tehrani, F. R. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.11.001 · Cited by 19
Ng, N. Y. H., Wu, H., Lau, E. S. H., Zhang, X., Yang, A., Tsang, A. Y. T., Yau, T., Kong, A. P. S., Ng, K., Chung, J. P. W., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110640 · Cited by 19
Bagheri, M., Rad, I. A., Jazani, N. H., Zarrin, R., Nanbakhsh, F., & Mohammadzaie, N. (2015) · PubMed Central · Cited by 19
Blood pressure in postmenopausal women with a history of polycystic ovary syndrome
Doroszewska, K., Milewicz, T., Mrozińska, S., Janeczko, J., Rokicki, R., Janeczko, M., Warzecha, D., & Marianowski, P. (2019) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2019.84039 · Cited by 19
“Schmidt [12] 2011 Cross-sectional 32 vs.”
BackgroundPourahmad, B., Majidnia, M., Saniee, N., Riyahifar, S., & Moradi, Y. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03927-5 · Cited by 18
Midlife women’s health consequences associated with polycystic ovary syndrome
Ali, A. T., & Guidozzi, F. (2019) · Climacteric · doi:10.1080/13697137.2019.1679111 · Cited by 18
Polycystic ovary syndrome: Metabolic consequences and long-term management
Carmina, E. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.936676 · Cited by 18
“Only one small study has reported data in older postmenopausal women who were affected by PCOS during their reproductive age [15].”
BackgroundLee, D. E., Park, S. Y., Park, S. Y., Lee, S. R., Chung, H. W., & Jeong, K. (2014) · Journal of Menopausal Medicine · doi:10.6118/jmm.2014.20.3.104 · Cited by 17
Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension
Shawky, N. M., Patil, C. N., Dalmasso, C., Maranon, R. O., Romero, D. G., Drummond, H. A., & Reckelhoff, J. F. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15504 · Cited by 16
Polycystic ovary syndrome and leukocyte telomere length: cross-sectional and longitudinal changes
Pölönen, J., Pinola, P., Ronkainen, J., Blakemore, A. I. F., Buxton, J. L., Tapanainen, J. S., Franks, S., Piltonen, T., Sebert, S. P., & Morin-Papunen, L. C. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0462 · Cited by 16
“13 numerous metabolic risk factors, do not seem to experience as many cardiometabolic events as might be expected (50,54,55), although opposite results have also been reported (45,46,56).”
ResultCardiovascular Disease in Older Women
Bayoumi, E., & Karasik, P. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.05.010 · Cited by 16
Herbert, S., & Woolf, K. (2023) · Nutrients · doi:10.3390/nu15245069 · Cited by 15
“PCOS is linked with increased prevalence of cardiometabolic risk factors, including dyslipidemia [10–13], hypertension [13–15], chronic inflammation, and impaired glucose tolerance [16,17], as well as overweight and obesity [18,19].”
BackgroundGuoqing, Z., Sun, F., Lihui, D., Bing, Y., Peng, Q., Yingting, W., & Jinxia, L. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2016.1149812 · Cited by 15
“Our results show that postmenopausal women with PCOS had a increased BMI, WHR and LDL-cholesterol, the higher FAI and lower SHBG levels which is consistent with some previous findings [17,22], but different from the study of Schmidt et al. [18].”
ResultInfluentialAksun, M. S., Sonu, N. C., Aygün, S., Karakulak, U. N., Mumusoglu, S., & Yıldız, B. O. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02230-0 · Cited by 15
“Schmidt et al. found that women with PCOS who had reached the postmenopausal period had a similar prevalence of type 2 diabetes compared to BMI and age-matched controls in a 21-year follow-up study of the Gothenburg PCOS cohort [11].”
Kiconco, S., Tay, C. T., Rassie, K. L., Azziz, R., Teede, H. J., & Joham, A. E. (2022) · Human Reproduction · doi:10.1093/humrep/deac077 · Cited by 14
Systems biology and in silico-based analysis of PCOS revealed the risk of metabolic disorders
Hossain, M. A., Ashik, S. A. A., Mahin, M. R., Amin, M. A., Rahman, M. H., Khan, M. A., & Emran, A. A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12480 · Cited by 14
Tepavčević, S., Milutinović, D. V., Μacut, D., Stanišić, J., Nikolič, M., Antić, I. B., Rodaljević, S., Bjekić-Macut, J., Matić, G. M., & Korićanac, G. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1548929 · Cited by 14
“, 1997), while data on increased frequency of myocardial infarction in PCOS women are controversial (Schmidt et al., 2011; Mani et al., 2013; Iftikhar et al., 2012; Dahlgren et al., 1992).”
BackgroundLau, L. H. Y., Nano, J., Prehn, C. P., Cecil, A., Rathmann, W., Zeller, T., Lechner, A., Adamski, J., Peters, A., & Thorand, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1000650 · Cited by 13
van der Ham, K., Koster, M. P. H., Velthuis, B. K., Budde, R. P. J., Fauser, B. C. J. M., Laven, J. S. E., & Louwers, Y. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165226 · Cited by 13
“However, this association no longer existed when this was assessed in postmenopausal women with a mean age of 70 years [12].”
BackgroundThe Polycystic Ovary Syndrome (PCOS)
Louwers, Y. V., & Laven, J. S. E. (2020) · Endocrinology · doi:10.1007/978-3-030-03594-5_3-1 · Cited by 13
Krentz, A. J., von Mühlen, D. G., & Barrett-Connor, E. L. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.001 · Cited by 13
“Scientific interest in the clinical consequences of PCOS in later life is gathering pace [21,22].”
BackgroundPandurevic, S., Bergamaschi, L., Pizzi, C., Patton, L., Rucci, P., Corzani, F., Cecchetti, C., Pelusi, C., Altieri, P., Vicennati, V., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0725 · Cited by 12
Polycystic Ovarian Morphology and Chronic Morbidity and Mortality in PCOS
Kugelman, N., Morris, D. V., Bastrash, M.-P., Feinberg, T., Miconiatis, S., Rehany, J., Tan, S. L., & Dahan, M. H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.40818 · Cited by 11
Wang, A., Corley, J., Jaswa, E. G., Lin, J., Smith, D. L., McCulloch, C. E., Huddleston, H. G., & Cedars, M. I. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.01.006 · Cited by 11
Gambineri, A., Rosa, S., Pandurevic, S., Cecchetti, C., Rotolo, L., Dionese, P., Belardinelli, E., Solmi, B., Zavatta, G., Fanelli, F., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf027 · Cited by 11
Nejabati, H. R., Samadi, N., Roshangar, L., & Nouri, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116843 · Cited by 11
Kataoka, J., Larsson, I., Lindgren, E., Kindstrand, L. O., Schmidt, J., & Stener‐Victorin, E. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-01022-0 · Cited by 11
Self-citationJanež, A., Herman, R., Poredoš, P., Mikhailidis, D. P., Blinc, A., Šabović, M., Studen, K. B., Jezovnik, M. K., Schernthaner, G.-H., Anagnostis, P. G., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611269146230920073301 · Cited by 11
Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome
Paterakis, T., & Diamanti‐Kandarakis, E. (2014) · Current Obesity Reports · doi:10.1007/s13679-014-0127-6 · Cited by 11
Heart Rate Changes in Electroacupuncture Treated Polycystic Ovary in Rats
Ramadoss, M., Ramanathan, G., Subbiah, A. J., & Natrajan, C. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/18303.7395 · Cited by 11
Sanchez, N. (2016) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-016-9543-6 · Cited by 11
Waldman, I. N., & Legro, R. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813209-8.00026-1 · Cited by 11
Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke
Havers‐Borgersen, E., Ekelund, C. K., Svendsen, P. F., Reinert, M. S., Vistisen, H. T., Butt, J. H., Østergaard, L., Schou, M., Køber, L., & Fosbøl, E. L. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf351 · Cited by 10
Endothelial dysfunction in subfertile women with polycystic ovary syndrome
Chen, L.-H., Lin, C., Wu, H., & Chu, P. (2022) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2022.11.013 · Cited by 10
Tuorila, K., Ollila, M., Hurskainen, E., Tapanainen, J. S., Franks, S., Piltonen, T., Kaikkonen, K., & Morin-Papunen, L. C. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae124 · Cited by 10
Wang, Z., Fleisch, A. F., Rifas‐Shiman, S. L., Calafat, A. M., James-Todd, T. M., Coull, B. A., Chavarro, J. E., Hivert, M., Whooten, R., Perng, W., et al. (2025) · Environmental Research · doi:10.1016/j.envres.2025.120786 · Cited by 10
Models of Hypertension in Aging
Reckelhoff, J. F., Cardozo, L. L. Y., & Fortepiani, M. L. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00052-x · Cited by 10
High androgen levels protect against hypothyroidism
Schmidt, J., Dahlgren, E., Bryman, I., Berntorp, K. E., Trimpou, P., Wilhelmsen, L., & Landin‐Wilhelmsen, K. (2016) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13054 · Cited by 10
Self-citationThe Polycystic Ovary Syndrome (PCOS)
Louwers, Y. V., & Laven, J. S. E. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_3 · Cited by 9
Mujica, L. K. S., Stein, C. S., Miyazato, L. G., Valente, F. S., Premaor, M. O., Antoniazzi, A. Q., Moresco, R. N., & Comim, F. V. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0077 · Cited by 8
“2,3,13,14 However, due to the great variability of clinical features in PCOS (obesity, presence of hyperandrogenism, dysglyce-mia, and different levels of atherosclerosis), a great variation of results is observed.”
Chahar, K., Sharma, Y. P., Kumar, M., Kumari, L., Mishra, L., Patel, P., & Kurmi, B. D. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100110 · Cited by 8
Meikle, A. W. (2012) · Yearbook of Medicine · doi:10.1016/s0084-3873(12)00334-3 · Cited by 8
The diagnosis and the reproductive and metabolic consequences of polycystic ovary syndrome
Abu-Faza, M., Abdelazim, I. A., Purohit, P., Shikanova, S., Zhurabekova, G., Karimova, B., Sarsembayev, M., & Starchenko, T. (2018) · Journal of Obstetrics and Gynecological Investigations · doi:10.5114/jogi.2018.79428 · Cited by 8
“The prevalence of PCOS is about 5–6%, but the prevalence rates reported are naturally dependent on the definition used and on the ethnicity of the studied population [3].”
BackgroundMethodInfluentialCardiovascular health and menopause in aging women with polycystic ovary syndrome
Helvacı, N., & Yıldız, B. O. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1719067 · Cited by 8
“The prevalence of T2DM in PCOS women was significantly higher at the initial study, but the difference was eliminated at late menopause [39].”
BackgroundOllila, M., Piltonen, T., Tapanainen, J. S., & Morin-Papunen, L. C. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.02.010 · Cited by 7
Contemporary Management of the Patient with Polycystic Ovary Syndrome
Francone, N. O., Ramirez, T., & Boots, C. E. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2023.08.003 · Cited by 7
Taha, R. F., Al-Ouqaili, M. T. S., & Abdullah, S. A. (2023) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2023.241.248 · Cited by 7
Excess mortality in mothers of patients with polycystic ovary syndrome
Louwers, Y. V., Roest-Schalken, M. E., Kleefstra, N., van Lennep, J. E. R., van den Berg, M. H., Fauser, B. C. J. M., Bilo, H. J. G., Sijbrands, E. J. G., & Laven, J. S. E. (2014) · Human Reproduction · doi:10.1093/humrep/deu107 · Cited by 7
“Studies assessing mortality rates of patients with PCOS and their family members are currently scarce due to small sample sizes and limited follow-up times of the patients (Pierpoint et al., 1998; Davies et al., 2011; Schmidt et al., 2011; Morgan et al., 2012).”
BackgroundPolycystic Ovary Syndrome Endocrine and Cardio-Metabolic Abnormalities: how to Manage?
Georgescu, C. E. (2015) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2015.77 · Cited by 7
Shawky, N. M., Dalmasso, C., Ojeda, N. B., Zuchowski, Y. P., Stachenfeld, N. S., Alexander, B. T., & Reckelhoff, J. F. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003067 · Cited by 7
SHULMAN, L. P. (2012) · Yearbook of Obstetrics Gynecology and Women s Health · doi:10.1016/j.yobg.2012.05.037 · Cited by 7
Vijayvergiya, R., Kapoor, D., Aggarwal, A., Sangwan, S., Suri, V., & Dhawan, V. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-2998-9 · Cited by 7
“[37] who reported that PCOD is not associated with CAD or mortality.”
BackgroundA decade in female reproduction: an endocrine view of the past and into the future
Μacut, D., Milutinović, D. V., Rašić-Marković, A., Brkljačić, J. M., Bjekić-Macut, J., & Stanojlović, O. P. (2018) · HORMONES · doi:10.1007/s42000-018-0073-x · Cited by 7
INCIDENCE OF NON - ALCOHOLIC HEPATIC FATTY INFILTRATION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
H, S. P. R., Balakrishna, B. V., Kudva, N., Sandhya, H., & Ramakrishna, P. (2014) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2014/133 · Cited by 7
“Non-alcoholic hepatic fatty infiltration is considered as the hepatic manifestation of MS since it worsens insulin resistance, predicts emergence of metabolic complications and increases the risk of cardiovascular events.([30]) Similarly, it seems appropriate to consider PCOS as the ovarian manifestation of MS.”
BackgroundPathophysiology of Ovarian Function in the Human Female
Franks, S., Hardy, K., & Conway, G. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00029-6 · Cited by 7
Combined Oral Contraceptives for Polycystic Ovary Syndrome: Pro and Contra (Review)
Мазеркина, И. А., Davydov, I. G., & Alyautdina, O. S. (2024) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2024-12-2-214-229 · Cited by 6
Mirzohreh, S., Ansari, A., Piroti, H., Khademi, R., Jahanbani, Y., & Alamdari, P. B. (2025) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.4274/tjod.galenos.2025.04680 · Cited by 6
Polycystic Ovary Syndrome (PCOS) Transition at Menopause
Shah, D., & Rasool, S. (2021) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_37_21 · Cited by 6
Peter, M. U., Areloegbe, S. E. J., Akintayo, C. O., Oniyide, A. A., Aturamu, A., & Olaniyi, K. S. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0176 · Cited by 6
Modern approaches to diagnostics of hyperandrogenism distributed forms in reproductive aged women
Бурка, О. А., & Tutchenko, T. М. (2019) · Reproductive Endocrinology · doi:10.18370/2309-4117.2019.46.39-45 · Cited by 6
Begum, I. A., Hosen, A. S. M. S., Ghimire, D., & Park, M. J. (2025) · Diagnostics · doi:10.3390/diagnostics15060711 · Cited by 5
25 historic papers: an ASRM 75th birthday gift from Fertility and Sterility
NIEDERBERGER, C. S., Pellicer, A., Simón, C., Kathrins, M. N., Goldstein, M., Sigman, M., Schlegel, P. N., Munné, S., Gardner, D. K., Cobo, A. C., et al. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.08.099 · Cited by 6
Kadhim, S. J., & Abdul-Hassan, I. A. (2017) · Iraqi journal of biotechnology · Cited by 5
The importance of lipid spectrum changes in women with polycystic ovary syndrome (PCOS)
Šarapatková, H., Sarapatka, J., & Fryšák, Z. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_110 · Cited by 5
“No distinctly higher incidence of cardiovascular illness has so far been proven in women with PCOS, but few studies have been carried out (14).”
BackgroundResultForslund, M., Landin‐Wilhelmsen, K., Brännström, M., & Dahlgren, E. (2023) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2023.04.008 · Cited by 5
Self-citationEndocrine-disrupting chemicals in polycystic ovary syndrome: an evidence-based minireview
Georgescu, C. E., Şuteu, M., & Georgescu, B. (2012) · Cited by 4
The effectiveness of exercise in the treatment of polycystic ovary syndrome
Kite, C. (2020) · Aston Publications Explorer (Aston University) · doi:10.48780/publications.aston.ac.uk.00042574 · Cited by 4
Elmugadam, A., Alhassan, S. M., Elfadil, G. A., Altoum, A. A., Ismail, M. K., & Ahmed, S. M. (2023) · International Journal of Biomedicine · doi:10.21103/article13(4)_oa5 · Cited by 3
A New Predictor for Insulin Resistance in Polycystic Ovary Syndrome: InsuTAG
Omma, T., Gökçe, A., Çelik, M., Karahan, İ., Çulha, C., & Gülçelik, N. E. (2023) · Current Women s Health Reviews · doi:10.2174/1573404820666230301115706 · Cited by 3
Fatima, Q., Jeelani, H., Abass, S., Farooq, M., & Rashid, F. (2023) · Springer eBooks · doi:10.1007/978-981-99-2193-5_9 · Cited by 3
Long-Term Morbidity: Cardiovascular Disease, Cancer, and Depression in PCOS
Milman, L. W., & Dokras, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_18 · Cited by 3
“In this cohort, women with PCOS did not have a signifi cantly increased risk of CV-related morbidity or mortality over the 21-year follow-up period, with subjects followed to a mean age of 70 years old [ 28 ].”
BackgroundMetabolic and lipoprotein aspects of polycystic ovarian syndrome
Pazderska, A., & Gibney, J. (2015) · Clinical Lipidology · doi:10.2217/clp.15.12 · Cited by 3
Al‐Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R. V., & Madden, L. A. (2019) · Endocrine · doi:10.1007/s12020-019-02059-9 · Cited by 3
Metadata
- Authors
- Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Schmidt, Johanna
- ORCID
- Brännström, Mats
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-12
- Volume
- 96
- Issue
- 12
- Pages
- 3794-3803
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2166647497
- Cited by
- 241
- References
- 44
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 22 · 2022: 24 · 2021: 16 · 2020: 17 · 2019: 14 · 2018: 15 · 2017: 18 · 2016: 11 · 2015: 21 · 2014: 26 · 2013: 13 · 2012: 14
- FWCI
- 19.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Västra Götalandsregionen
- Vetenskapsrådet
- Sahlgrenska Universitetssjukhuset
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- polycystic ovary syndrome, postmenopausal women, cardiovascular disease, cardiovascular risk factors, hypertension, triglycerides, myocardial infarction, stroke, mortality, metabolic syndrome, long-term follow-up
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Cholesterol, Female, Follow-Up Studies, Humans, Insulin, Middle Aged, Polycystic Ovary Syndrome, Registries, Risk Factors, Triglycerides, Incidence, Prevalence, Postmenopause
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.